Literature DB >> 31152084

Characteristics of BRAF V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients.

Christelle de la Fouchardière1, Romain Cohen2, David Malka3, Rosine Guimbaud4, Héloïse Bourien5, Astrid Lièvre6, Wulfran Cacheux7, Pascal Artru8, Eric François9, Marine Gilabert10, Emmanuelle Samalin-Scalzi11, Aziz Zaanan12, Vincent Hautefeuille13, Benoit Rousseau14, Hélène Senellart15, Romain Coriat16, Ronan Flippot3, Françoise Desseigne17, Audrey Lardy-Cleaud18, David Tougeron19.   

Abstract

BACKGROUND: BRAF V600E mutations occurring in about 10% of metastatic colorectal cancers (mCRCs) are usually associated with a poor outcome. However, their prognostic factors are unknown.
MATERIALS AND METHODS: We built a multicenter clinico-biological database gathering data from patients with BRAF V600E -mutant mCRC treated in one of the 16 French centers from 2006 to 2017. The primary endpoint was to identify prognostic factors using a Cox model.
RESULTS: We included 287 patients (median age, 67 years [28-95]; female, 57%). Their median overall survival was 20.8 months (95% confidence interval [CI], 17.97-27.04), and median progression-free survival in the first-line setting was 4.34 months (95% CI, 3.81-5.03). Chemotherapy regimen and biological agents (antiangiogenic or anti-epidermal growth factor receptor) were not associated with overall and progression-free survival. Stage IV disease (synchronous metastases) and absence of curative-intent surgery were statistically associated with poor overall survival. Among the 194 patients with mismatch repair (MMR) status available, overall survival was significantly longer in patients with deficient MMR tumors compared with those with proficient MMR tumors (adjusted hazard ratio = 0.56; p = .009).
CONCLUSION: Despite that BRAF V600E -mutant mCRCs are associated with poor overall and progression-free-survival, patients with deficient MMR tumors and/or resectable disease experienced a longer survival. These results highlight the importance of MMR testing and resectability discussion in patients with BRAF V600E mCRC in day-to-day practice. IMPLICATIONS FOR PRACTICE: Mismatch repair (MMR) testing and resectability discussion in patients with BRAF V600E metastatic colorectal cancer (mCRC) should be performed in day-to-day practice to steer treatment decision making in patients with BRAF V600E -mutant mCRC. © AlphaMed Press 2019.

Entities:  

Keywords:  BRAF; Colorectal cancer; Decision making; Mismatch repair testing; Prognostic

Year:  2019        PMID: 31152084      PMCID: PMC6975964          DOI: 10.1634/theoncologist.2018-0914

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  43 in total

1.  Final results of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC).

Authors:  M Geissler; A Tannapfel; A Reinacher-Schick; U Martens; J Ricke; J Riera-Knorrenschield; S Kanzler; S Held; V Heinemann; T Seufferlein; D Modest
Journal:  Ann Oncol       Date:  2019-12-04       Impact factor: 32.976

2.  The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

Authors:  Stephen B Edge; Carolyn C Compton
Journal:  Ann Surg Oncol       Date:  2010-06       Impact factor: 5.344

3.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

Authors:  Eric Van Cutsem; Claus-Henning Köhne; István Láng; Gunnar Folprecht; Marek P Nowacki; Stefano Cascinu; Igor Shchepotin; Joan Maurel; David Cunningham; Sabine Tejpar; Michael Schlichting; Angela Zubel; Ilhan Celik; Philippe Rougier; Fortunato Ciardiello
Journal:  J Clin Oncol       Date:  2011-04-18       Impact factor: 44.544

4.  Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials.

Authors:  Matthieu Faron; Jean-Pierre Pignon; David Malka; Abderrahmane Bourredjem; Jean-Yves Douillard; Antoine Adenis; Dominique Elias; Olivier Bouché; Michel Ducreux
Journal:  Eur J Cancer       Date:  2014-11-24       Impact factor: 9.162

Review 5.  Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.

Authors:  Matthew Dankner; April A N Rose; Shivshankari Rajkumar; Peter M Siegel; Ian R Watson
Journal:  Oncogene       Date:  2018-03-15       Impact factor: 9.867

6.  KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.

Authors:  Susan D Richman; Matthew T Seymour; Philip Chambers; Faye Elliott; Catherine L Daly; Angela M Meade; Graham Taylor; Jennifer H Barrett; Philip Quirke
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

7.  Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients.

Authors:  Johan Gagnière; Aurélien Dupré; Sepideh S Gholami; Denis Pezet; Thomas Boerner; Mithat Gönen; Thomas P Kingham; Peter J Allen; Vinod P Balachandran; Ronald P De Matteo; Jeffrey A Drebin; Rona Yaeger; Nancy E Kemeny; William R Jarnagin; Michael I D'Angelica
Journal:  Ann Surg       Date:  2020-01       Impact factor: 12.969

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

9.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

10.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Authors:  Federica Di Nicolantonio; Miriam Martini; Francesca Molinari; Andrea Sartore-Bianchi; Sabrina Arena; Piercarlo Saletti; Sara De Dosso; Luca Mazzucchelli; Milo Frattini; Salvatore Siena; Alberto Bardelli
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544

View more
  3 in total

1.  Treating BRAFV600E metastatic colorectal patients in 2019: a BEACON of hope?

Authors:  Christelle de la Fouchardiere
Journal:  Ann Transl Med       Date:  2019-11

2.  Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study.

Authors:  Sahir Javed; Stéphane Benoist; Patrick Devos; Stéphanie Truant; Rosine Guimbaud; Astrid Lièvre; David Sefrioui; Romain Cohen; Pascal Artru; Aurélien Dupré; Jean-Baptiste Bachet; Christelle de la Fouchardière; Anne Ploquin; Anthony Turpin
Journal:  World J Surg Oncol       Date:  2022-04-23       Impact factor: 3.253

3.  The Prognostic Value of Locoregional Interventions for BRAF V600E Metastatic Colorectal Cancer: A Retrospective Cohort Analysis.

Authors:  Liu-Fang Ye; Xiao-Meng Ji; Chao Ren; Zhi-Qiang Wang; Chun-Ping Lin; Dong-Liang Chen; Yan-Qing Cai; Ying Jin; Miao-Zhen Qiu; Zi-Ming Du; Shao-Yan Xi; Dong-Sheng Zhang; Feng Wang; Feng-Hua Wang; Rui-Hua Xu; Yu-Hong Li; De-Shen Wang
Journal:  Biomolecules       Date:  2021-08-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.